Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Campbell Alliance, Novella and Hovione.
Micheal Turner has taken the helm at newly formed Campbell Alliance subsidiary Ecuity Research.
On Tuesday Campbell – the analytics division for inVentiv Health – received Federal Trade Commission (FTC) clearance for the acquisition of two former SDI Health companies, which now form Ecuity.
The new firm will provide services in quantitative research and analytics, opinion leader mapping, as well as syndicated audits.
Having spent six years with Campbell, most recently as VP of brand marketing practice, CEO Nader Naeymi-Rad said Turner’s involvement in the company’s growth secured him the new role.
He said: “Michael has played a key role in our growth, demonstrated great commitment, and delivered success”.
Supply chain specialist CFAO has named Alain Pécheur as CFO.
Pécheur, who will also join the board of directors, has worked for the company since 1992.
He has moved his way up through the ranks from auditor to financial controller, finally becoming the director of finance and administrative affairs for the automotive section of the business in 2005.
Healthcare adverstising advisor AbelsonTaylor has appointed Sabrina Ray as user experience designer, and John Mullen as program analyst.
Ray joins the firm from Razorfish where she worked on interactive programs for Microsoft, and LG. In her new role she will develop visual representations for use in websites, mobile applications, and trade shows.
Mullen, who will be responsible for analytic and project management across all brands, was previously an analyst at Draftfcb, where he worked on developing measurement for the healthcare team.
Hovione has appointed Colin Minchom as VP of its particle design business unit.
Minchom joins the firm from Patheon, where he was VP of pharmaceutical development services for North America.
"Dr. Minchom is now responsible for innovating Hovione's Pharmaceutical Particle Design offerings to meet the development and commercial supply needs of the formulator with poorly bioavailable or otherwise challenging molecules," said CEO Guy Villax.
Novella Clinical has drafted in Colleen Dureau-Inzerillo as global head of business development.
In her new role, she will lead sales strategy and implementation through Novella Clinical Resourcing’s (NCR) field sales group.
Novella Clinical executive VP of business development Nick Dyer said: “Colleen brings a strong background in business development, a keen understanding of the challenges facing pharmaceutical clients and both the energy and talent to accelerate the growth of NCR while providing value to our clients.”